1
|
Shimozawa K, Yagasaki H, Kanezawa K, Morioka I. Cerebral infarction in a patient with inhibitor-positive hemophilia B treated with plasma-derived factor VIIa and factor X mixture. Ann Hematol 2024; 103:2161-2162. [PMID: 38609725 DOI: 10.1007/s00277-024-05729-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2023] [Accepted: 03/23/2024] [Indexed: 04/14/2024]
Affiliation(s)
- Katsuyoshi Shimozawa
- Paediatrics, Nihon University Itabashi Hospital, 30-1 Oyaguchi kami-cho, Itabashi-ku, Tokyo, 173-8610, Japan
| | - Hiroshi Yagasaki
- Paediatrics, Nihon University Itabashi Hospital, 30-1 Oyaguchi kami-cho, Itabashi-ku, Tokyo, 173-8610, Japan.
| | - Koji Kanezawa
- Paediatrics, Nihon University Itabashi Hospital, 30-1 Oyaguchi kami-cho, Itabashi-ku, Tokyo, 173-8610, Japan
| | - Ichiro Morioka
- Paediatrics, Nihon University Itabashi Hospital, 30-1 Oyaguchi kami-cho, Itabashi-ku, Tokyo, 173-8610, Japan
| |
Collapse
|
2
|
Takeyama M, Furukawa S, Ogiwara K, Tamura S, Ohno H, Higasa S, Shimonishi N, Nakajima Y, Onishi T, Nogami K. Coagulation potentials of plasma-derived factors VIIa and X mixture (Byclot ® ) evaluated by global coagulation assay in patients with acquired haemophilia A. Haemophilia 2024; 30:249-252. [PMID: 38031253 DOI: 10.1111/hae.14902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2023] [Revised: 11/16/2023] [Accepted: 11/17/2023] [Indexed: 12/01/2023]
Affiliation(s)
- Masahiro Takeyama
- Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
- Divison of Hemophilia, National Hospital Organization, Osaka National Hospital, Osaka, Osaka, Japan
| | - Shoko Furukawa
- Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
| | - Kenichi Ogiwara
- Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
| | - Shinobu Tamura
- Department of Hematology, Wakayama Medical University, Wakayama, Wakayama, Japan
| | - Hitoshi Ohno
- Department of Hematology, Tenri Hospital, Tenri, Nara, Japan
| | - Satoshi Higasa
- Department of Respiratory Medicine and Hematology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - Naruto Shimonishi
- Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
- The Course of Thrombosis and Hemostasis Molecular Pathology, Nara Medical University, Kashihara, Nara, Japan
| | - Yuto Nakajima
- Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
- Advanced Medical Science of Thrombosis and Hemostasis, Nara Medical University, Kashihara, Nara, Japan
| | - Tomoko Onishi
- Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
- Center for Postgraduate Training Nara Medical University Hospital, Kashihara, Nara, Japan
| | - Keiji Nogami
- Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
| |
Collapse
|
3
|
Okayama Y, Bingo M, Sakatoku K, Okamura H, Nanno S, Nishimoto M, Nakashima Y, Koh H, Hino M, Nakamae H. The safety of the combination therapy of recombinant factor VIIa and plasma-derived factor VIIa and factor X for refractory hemorrhage in acquired hemophilia A. Blood Coagul Fibrinolysis 2023; 34:419-422. [PMID: 37577920 DOI: 10.1097/mbc.0000000000001243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/15/2023]
Abstract
Acquired hemophilia A (AHA) is a rare, life-threatening hemorrhagic disease caused by autoantibodies against factor VIII (FVIII), and bypassing agents (BPA) are used to control bleeding. However, some cases need a change of BPA or BPAs given sequentially or in combination for refractory bleeding. A 71-year-old man was admitted with subcutaneous hemorrhage. Laboratory investigations showed prolongation of activated partial thromboplastin time (APTT) and low-coagulation FVIII activity and FVIII inhibitor; we, therefore, diagnosed AHA. He was treated with recombinant factor VIIa (rFVIIa) BPA and prednisolone. However, his symptoms did not improve sufficiently, thus we switched BPA to activated prothrombin complex concentrate. Unfortunately, this was not effective and he suffered hemorrhagic shock. Therefore, we selected rFVIIa, with plasma-derived FVIIa and factor X (pd-FVIIa/FX) as combination therapy, and hemostasis was achieved without thrombosis. This case suggests that the combination of rFVIIa and pd-FVIIa/FX short-term can be well tolerated for refractory hemorrhage in AHA.
Collapse
Affiliation(s)
- Yusuke Okayama
- Department of Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka
| | - Masato Bingo
- Department of Laboratory Medicine, Tokyo Medical University, Tokyo, Japan
| | - Kazuki Sakatoku
- Department of Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka
| | - Hiroshi Okamura
- Department of Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka
| | - Satoru Nanno
- Department of Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka
| | - Mitsutaka Nishimoto
- Department of Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka
| | - Yasuhiro Nakashima
- Department of Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka
| | - Hideo Koh
- Department of Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka
| | - Masayuki Hino
- Department of Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka
| | - Hirohisa Nakamae
- Department of Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka
| |
Collapse
|
4
|
Effects of low and high factor X concentrations on thrombin generation in vitro. THROMBOSIS UPDATE 2022. [DOI: 10.1016/j.tru.2022.100111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|